Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Novel Diagnostic Pathway for Immediate Type Hypersensitivity Reactions to Teicoplanin, Including Invivo and Ex-vivo Testing Modalities.

NCT03210233 is registered in ClinicalTrials.gov with The Leeds Teaching Hospitals NHS Trust as lead sponsor.

NCT NCT03210233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03210233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Novel Diagnostic Pathway for Immediate Type Hypersensitivity Reactions to Teicoplanin, Including Invivo and Ex-vivo Testing Modalities.
Lead sponsor
The Leeds Teaching Hospitals NHS Trust
Phase
Not applicable
Overall status
Unknown status
Start date
March 1, 2017
Completion date
May 31, 2021
Enrollment
548 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypersensitivity